Florida Attorney General Subpoenas CVS Health Over Alleged Pharmacy-Benefit Steering

Florida’s attorney general has issued a subpoena to CVS Health, according to a report published Monday by Yahoo Finance, as part of an investigation into the company’s pharmacy benefit-management practices. The inquiry centers on whether CVS’s pharmacy benefit manager, which helps administer prescription drug coverage, may be steering patients toward CVS-owned pharmacies.

The attorney general’s examination, as described in the report, focuses on the relationship between pharmacy benefit administration and pharmacy selection. Pharmacy benefit managers, or PBMs, typically handle tasks such as negotiating drug reimbursement rates with insurers and networks, which can influence which pharmacies patients use and what they pay.

In the Yahoo Finance account, the state’s legal action indicates that Florida is looking beyond general pricing and contract terms, and instead questioning whether incentives or operational choices could affect patients’ access to a particular pharmacy chain. For CVS Health, the matter touches directly on a business line that includes both retail pharmacy operations and the PBM function that supports them.

For context, CVS Health operates across multiple parts of the prescription drug channel. That includes retail pharmacy stores and the PBM-related services that can affect prescription coverage and pharmacy networks for insurers and other payers. When PBMs also own pharmacies, critics have sometimes argued that the structure can create incentives to favor affiliated locations.

The report does not spell out the specific documents sought in the subpoena, the scope of the time period under review, or whether CVS has provided any response. It also does not indicate whether the attorney general has filed additional legal claims, sought interim relief, or identified particular practices at issue beyond the question of steering patients to CVS pharmacies.

CVS Health did not provide a quoted statement in the Yahoo Finance post described in the report. Without details on the state’s allegations, CVS’s position, or the subpoena’s breadth, it is not possible to assess the strength of the claims or whether the matter will lead to regulatory action, litigation, or a negotiated resolution.

As with many PBM-related investigations, the outcome may hinge on evidence about how patients are directed to pharmacies in practice, including what controls are used to build networks, how referrals or recommendations work, and whether disclosures to patients and plan sponsors are sufficient. The attorney general’s next procedural steps, including any follow-up filings, could also shape how quickly the inquiry progresses.

What to watch next is whether CVS publicly addresses the subpoena, what information the attorney general ultimately requests or receives, and whether the state provides additional descriptions of the practices under review. If more jurisdictions join similar investigations, the issue could also intensify policy scrutiny of PBM practices and insurer-pharmacy relationships.